Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2000;101:856-861

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fujiwara, N.
Right arrow Articles by Okumura, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujiwara, N.
Right arrow Articles by Okumura, K.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*(L)-ARGININE
*NITRIC OXIDE
Medline Plus Health Information
*Dietary Sodium
*High Blood Pressure
Related Collections
Right arrow Other hypertension
Right arrow Endothelium/vascular type/nitric oxide

(Circulation. 2000;101:856.)
© 2000 American Heart Association, Inc.


Clinical Investigation and Reports

Study on the Relationship Between Plasma Nitrite and Nitrate Level and Salt Sensitivity in Human Hypertension

Modulation of Nitric Oxide Synthesis by Salt Intake

Naoto Fujiwara, MD; Tomohiro Osanai, MD; Takaatsu Kamada, MD; Takeshi Katoh, MD; Koki Takahashi, MD; Ken Okumura, MD

From the Second Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki, Japan.

Correspondence to Tomohiro Osanai, MD, The Second Department of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562, Japan.


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background—High salt intake suppresses the effect of nitric oxide (NO) in the peripheral resistance vessels in animal models. We tested the hypothesis that the modulation of endogenous NO is related to salt sensitivity in human hypertension.

Methods and Results—Inpatients with essential hypertension (n=24) were maintained on a normal-salt diet (12 g/d NaCl) for 3 days, a low-salt diet (2 g), a high-salt diet (20 to 23 g), and a low-salt diet for 7 days. Normotensive subjects (n=16) were maintained on the first 2 salt diets. The hypertensive patients whose average 24-hour blood pressure was increased by >5% by salt loading were assigned to group 1 (n=8) and the others to group 2 (n=16). Nitrate plus nitrite (NOx) was measured by the Griess method, and asymmetrical dimethylarginine (ADMA) by high-performance liquid chromatography. The plasma NOx level during the normal-salt diet was lower in group 1 than in group 2 and the normotensive group. After salt loading, the plasma NOx level was decreased and reversed after the second salt restriction. Plasma ADMA level was increased after salt loading and decreased after salt restriction. The change in plasma NOx level was correlated inversely with those in blood pressure (r=-0.59, P=0.0007) and plasma ADMA level (r=-0.64, P=0.003) after salt loading and restriction.

Conclusions—Modulation of NO synthesis by salt intake may be involved in a mechanism for salt sensitivity in human hypertension, presumably via the change in ADMA.


Key Words: nitric oxide • sodium • hypertension


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Nitric oxide (NO) contributes to vessel homeostasis by inhibiting vascular smooth muscle tone1 and growth,2 platelet aggregation,3 and leukocyte adhesion to the endothelium.4 Previous studies on the relationship between NO synthesis and salt intake showed that dietary salt loading had no effect on NO production in the peripheral hindquarter circulation in the rat,5 although it enhanced the urinary excretion of nitrite and nitrate (NOx) as well as cGMP.6 In Dahl/Rapp salt-resistant rats, ingestion of a high-salt diet impaired the myogenic response of renal afferent arterioles7 and the dilator response of large cerebral collateral arterioles to cerebral occlusion.8 It is suggested that high salt intake suppresses NO production or the effect of NO in the peripheral resistance vessels and may affect systemic arterial blood pressure (BP). Even in humans, high salt intake was demonstrated to attenuate NO production.9 However, little attention has been paid to the relationship between endogenous NO level and the change in BP after salt loading, so-called salt sensitivity.

Analogues of L-arginine, such as asymmetrical dimethyl-L-arginine (ADMA) and NG-monomethyl-L-arginine (L-NMMA), are competitive inhibitors of NO synthase (NOS). ADMA is produced by endothelial cells in culture10 and blood vessels11 and is present in plasma and urine of rats and human subjects,12 13 14 suggesting that ADMA may be an endogenous inhibitor of NOS in vivo. The renal excretion of ADMA has been shown to be increased in Dahl salt-sensitive rats compared with that in the salt-resistant rat fed a high-salt diet, and it is correlated with the level of BP.15 In the present study, we investigated the relationship between endogenous NO production and salt sensitivity in patients with essential hypertension (EH) and, in addition, the role of ADMA in salt sensitivity.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Subjects
Twenty-four patients with EH (15 men and 9 women; mean age, 50 years; range, 20 to 72 years) and 13 normotensive control subjects (11 men and 2 women; mean age, 47 years; range, 20 to 73 years) were investigated after informed consent was obtained from each subject. The study protocols, including salt loading and restriction in the patients with EH and salt restriction in the normotensive subjects, were approved by the Ethics Committee of the University Hospital. The patients with EH had mild to moderate hypertension, with casual clinic systolic BP between 150 and 180 mm Hg and diastolic BP between 90 and 115 mm Hg. Patients with secondary hypertension were excluded by physical examination, urinalysis, adrenal CT scan, renal arteriography, and hormonal examinations, such as plasma renin activity (PRA), plasma aldosterone concentration, plasma catecholamine concentration, and 24-hour urinary excretions of 17-hydrocorticosteroids and 17-ketosteroids. Normotensive control subjects were admitted for the evaluation of their atypical chest pain, and the coronary arteriographic examination revealed normal findings. The study was performed when each patient/subject was admitted to our hospital.

Protocol
In the patients with EH, all antihypertensive medications were discontinued >=2 weeks before admission. They maintained a constant daily activity pattern, getting up at 6 AM and going to bed at 9 PM, and were subjected to specific diets arranged by the amount of salt and containing a constant amount of nitrate. They received a series of normal-salt diet (12 g/d NaCl and 500 µmol/d nitrate) for 3 days, low-salt diet (2 g/d NaCl and 500 µmol/d nitrate) for 7 days, high-salt diet (20 to 23 g/d NaCl and 600 µmol/d nitrate) for 7 days, and then low-salt diet for 7 days. Compliance with the prescribed diet was assessed by the measurements of 24-hour urinary sodium excretion on the last days of the low- and high-salt diets.

Blood was drawn from all subjects at 6 AM on the last day of the normal-salt diet for the determination of serum cholesterol, triglyceride, creatinine, sodium, potassium, and chloride concentrations; PRA; and plasma concentrations of aldosterone, norepinephrine (NE), epinephrine, and NOx. On the last day of each salt diet, every 30-minute noninvasive ambulatory BP monitoring was carried out for 24 hours with the use of ABPM-630 (Nippon Kohrin Co). The patients with EH were divided into 2 groups according to the response to salt loading. When the average of the mean BP [(systolic BP - diastolic BP)/3 + diastolic BP] measured for 24 hours on the last day of the high-salt diet exceeded by >5% the average on the last day of the low-salt diet, the patients were classified as group 1. When the increase in the average of mean BP was <5%, the patients were classified as group 2. Blood specimens for the subsequent determinations of PRA and plasma concentrations of aldosterone, ADMA, and NE were obtained from the brachial vein at 6 AM after overnight fasting on the last days of the low- and high-salt diets and that for plasma concentration of NOx on the last days of the normal-, low-, and high-salt diets. All subjects were asked to record daily activities and their times and to refrain from smoking during the study period.

Normotensive control subjects were administered the normal-salt diet (12 g/d NaCl and 500 µmol/d nitrate) for 3 days and the low-salt diet (2 g/d NaCl and 500 µmol/d nitrate) for 7 days. On the last days of the normal- and low-salt diets, every 30-minute noninvasive ambulatory BP monitoring was carried out for 24 hours with ABPM-630, and blood was sampled at 6 AM for the subsequent determination of serum cholesterol, triglyceride, creatinine, sodium, potassium, and chloride concentrations and plasma NOx concentration.

NOx Analysis
Plasma NOx levels were measured with the Griess method. Briefly, after being passed through 50-kD ultrafilters, 40 µL of the plasma was diluted with 240 µL assay buffer and mixed with 10 µL cofactor and 10 µL nitrate reductase (NOx colorimetric assay kit, Cayman Chemical Co). After the plasma had been kept at room temperature for 3 hours to convert nitrate to nitrite, total nitrite was measured at 540 nm absorbance by reaction with Griess reagent (sulfanilamide and naphthalene–ethylene diamine dihydrochloride). Amounts of nitrite in the plasma were estimated by a standard curve obtained from enzymatic conversion of NaNO3 to nitrite.

ADMA Analysis
Plasma (1 mL) was mixed with 2 mL of 10% trichloroacetic acid, put on ice for 10 minutes, and centrifuged at 2500g for 15 minutes. The resulting supernatant was evaporated under vacuum to dryness and was then loaded to a Bond Elut PRS column (Varian Associates Inc). After a washing with 10 mL of 1 mol/L pyridine, ADMA was eluted by 10 mL of 3 mol/L ammonia and was again evaporated under vacuum to dryness. The extract was incubated with 20 µL phenylthiocarbamoyl solution (ethanol:triethylamine:water:phenyl isothiocyanate 7:1:1:1, vol/vol) for 20 minutes at room temperature. The dried samples were applied on reverse-phase high-performance liquid chromatography (HPLC) with a YMC-Pack ODS-AM column (YMC Co) and 60 mmol/L acetic buffer (pH 6.6)/0.05% trifluoroacetic acid elution with a linear gradient of acetonitrile ranging from 6% to 60% over a period of 25 minutes at a flow rate of 1 mL/min. Amounts of ADMA in the plasma were estimated from a standard curve of synthetic ADMA (Sigma Chemical Co).

Analysis of Other Variables
Serum sodium, potassium, and chloride ion concentrations were measured with a flame photometer. Serum cholesterol, triglyceride, and creatinine concentrations were measured by an autoanalyzer method. Plasma NE and epinephrine concentrations were measured by HPLC. PRA and plasma aldosterone concentration were measured by radioimmunoassay.

Statistics
Values are shown as mean±SEM. Differences of mean values were assessed by a paired or unpaired Student’s t test for comparison of 2 variables and by ANOVA for comparison of multiple variables. Relationships between 2 continuous variables were assessed by a regression analysis using the Pearson correlation coefficient. Differences in sex and smoking habit between normotensive and hypertensive groups were analyzed by {chi}2 test. A value of P<0.05 was considered statistically significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Patient Profiles
Table 1Down shows clinical characteristics for normotensive subjects and EH patients. Eight EH patients showed a response of the increase in mean BP by >5% after salt loading (group 1), whereas the other 16 showed no or little response (group 2). The distribution of age, sex, height, weight, and smoking habit did not differ among the 3 groups. No significant difference in serum cholesterol, serum triglyceride, electrolytes, and creatinine concentrations was detected among the 3 groups. PRA, plasma aldosterone, and NE concentrations were 1.2±0.2 ng · mL-1 · h-1, 126±12 pg/mL, and 260±20 pg/mL in patients with EH, respectively. As demonstrated in Table 2Down, the mean BP was significantly decreased after the first salt restriction, increased after salt loading, and again decreased after the second salt restriction in group 1, whereas it was unchanged in group 2. In the normotensive subjects, the mean BP, which was significantly lower than that in the patients with EH during the normal-salt diet, was not affected by salt restriction. Urinary sodium excretion was 30±3 and 28±3 mEq/d on the last day of the low-salt diet in the normotensive subjects and the patients with EH, respectively, and 342±20 mEq/d on the last day of the high-salt diet in the patients with EH.


View this table:
[in this window]
[in a new window]
 
Table 1. Clinical Characteristics of Patients With EH and Normotensive Control Subjects


View this table:
[in this window]
[in a new window]
 
Table 2. Change in Mean BP After Salt Restriction and Loading in Patients With EH and Normotensive Control Subjects

Effects of Salt Intake on Plasma NOx and NE Concentrations
As shown in Figure 1Down, the plasma NOx concentration during the normal-salt diet was 35.4±9.1 µmol/L in the normotensive subjects, 35.1±5.9 µmol/L in group 2, and 22.3±3.7 µmol/L in group 1 (normotensive versus group 1, P<0.05; group 2 versus group 1, P<0.05). In the normotensive subjects, the plasma NOx concentration after salt restriction was 45.6±12.2 µmol/L (P=NS). In group 2, the plasma NOx concentration was 42.0±5.4 µmol/L after the first salt restriction (P=NS) and then decreased significantly (P<0.05) after salt loading and increased (P<0.05) after the second salt restriction. In group 1, it was increased significantly to 50.7±14.3 µmol/L (P<0.05) after the first salt restriction, decreased significantly to 18.6±5.2 µmol/L after salt loading (P<0.05 versus value after the first salt restriction), and reversed to the previous value (30.3±9.5 µmol/L) after the second salt restriction (P<0.05 versus value after salt loading). The plasma NOx concentration level was similar among the 3 groups during the first low-salt diet, significantly lower in group 1 than in group 2 during the high-salt diet (P<0.05), and again similar between groups 1 and 2 during the second low-salt diet.



View larger version (20K):
[in this window]
[in a new window]
 
Figure 1. Plasma NOx concentrations on last day of each salt diet period in normotensive subjects and in hypertensive patients with EH. Hypertensive patients whose average 24-hour BP was increased by >5% by salt loading were assigned to group 1 (n=8) and others to group 2 (n=16).

Figure 2Down demonstrates a relationship between the changes in mean BP after salt loading (from 2 g/d to 20 to 23 g/d) and restriction (from 20 to 23 g/d to 2 g/d), ie, salt sensitivity, and the change in plasma NOx concentration in the patients with EH. There was a significant inverse correlation between the percent changes in mean BP and plasma NOx concentration after salt loading and restriction (r=-0.59, P=0.0007): a significant negative correlation was found in salt loading, as shown by the open circles (r=-0.43, P<0.05), and a weak correlation in salt restriction, as shown by the closed circles (r=-0.49, P=0.062).



View larger version (18K):
[in this window]
[in a new window]
 
Figure 2. Relationship between percent change in mean BP and percent change in plasma NOx concentration after salt loading and restriction in patients with EH.

The plasma NE concentration and PRA were decreased significantly after salt loading, from 305±40 to 133±13 pg/mL (P<0.05) and from 2.7±0.6 to 0.5±0.1 ng · mL-1 · h-1 (P<0.05), respectively, in the patients with EH. Neither the percent change in the plasma NE concentration (Figure 3Down) nor that in PRA was correlated with the percent change in mean BP after salt loading and restriction.



View larger version (15K):
[in this window]
[in a new window]
 
Figure 3. Relationship between percent change in mean BP and percent change in plasma NE concentration after salt loading and restriction in patients with EH.

Effect of Salt Loading on Plasma ADMA Concentration
Salt loading resulted in a significant increase in the plasma ADMA concentration, from 1.86±0.28 to 2.23±0.24 µmol/L, in the patients with EH (P<0.05), whereas salt restriction elicited a significant decrease, to 1.76±0.24 µmol/L (P<0.05). As shown in Figure 4Down, the percent change in plasma ADMA concentration was significantly inversely correlated with the percent change in plasma NOx concentration after salt loading and restriction (r=-0.64, P=0.003).



View larger version (20K):
[in this window]
[in a new window]
 
Figure 4. Relationship between percent change in plasma ADMA concentration and NOx concentration after salt loading and restriction in patients with EH.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
Modulation of NO Synthesis by Salt Intake
Previous studies showed that NO production in response to high salt intake may be impaired in EH patients. Higashi et al16 demonstrated that salt loading attenuates the conversion of L-arginine to NO in the endothelium of the renal vasculature in salt-sensitive patients with EH, which was assessed by L-arginine–induced renovascular relaxation and the increase in plasma cGMP in response to L-arginine. Stein et al17 showed that the administration of a high-salt diet to normotensive subjects does not alter NO-mediated vascular responsiveness, which was determined by methacholine-induced increase in forearm blood flow. However, these methods are not specific for the assessment of NO synthesis. Methacholine and L-arginine can cause vascular dilatation by mechanisms other than the generation of NO, and cGMP is also a second messenger of atrial natriuretic peptide. An increased breakdown of NO by free radicals may be another possible mechanism for salt-induced impairment of NO-mediated vasorelaxation. In experimental animals, such as spontaneously hypertensive rats, stroke-prone spontaneously hypertensive rats, and Dahl salt-sensitive rats, after a high-salt diet, superoxide production is enhanced in vessels, which was assessed by the effects of superoxide dismutase and direct measurement.18 19 Vitamin C has been shown to improve endothelium-dependent vasodilation in patients with EH,20 suggesting that superoxide radicals function as a scavenger of NO in vivo in basal conditions.

NO is rapidly oxidized to nitrite and then to nitrate by oxygenated hemoglobin, molecular oxygen, and superoxide anions and is excreted as such into the urine. Thus, NOx measurement seems to be a direct method for measurement of NO production. The main drawback of the use of the total nitrate as a measure of NO synthesis is that nitrate may arise from sources other than the metabolism of NO. In mammalian cells, however, NO is synthesized from the guanidino nitrogen atoms of the amino acid L-arginine, and this is the only known route by which these nitrogen atoms may be incorporated into nitrate. Therefore, the measurement of total nitrate may be a specific indicator of total body NO synthesis. However, the measurement of endogenously generated nitrate may be confounded by several factors. The most important factor is the contribution of dietary nitrate to plasma NOx. NO inhaled via tobacco smoke is another source of nitrate.

Campese et al9 showed that high salt intake decreases plasma NOx concentration in black hypertensive patients but did not describe the nitrate content in salt diets. Because the half-life of nitrate was {approx}8 hours, {approx}67% of exogenously derived nitrate seems to be cleared from the plasma after overnight fasting. It is also possible that the patients failed to adhere to the high-salt diet. However, adherence to the diet was confirmed by the measurement of urinary sodium excretion in the present study. On the basis of the constant daily intake of nitrate and the stability of daily activities during the study period, our results indicate that plasma NOx concentration is decreased after salt loading, even though the high-salt diet included more nitrate than the low-salt diet. In contrast to salt loading, salt restriction significantly increased the plasma NOx concentration, further indicating that endogenous NO production is modulated by salt intake.

The main purpose of the present study was to elucidate whether endogenous NO production is related to salt sensitivity in human hypertension. The result showed that the plasma NOx concentration was significantly lower in group 1 EH patients than in group 2 during the high-salt diet, whereas it was similar between groups 1 and 2 during the low-salt diet. Furthermore, the changes in the plasma NOx concentration after salt loading and restriction were significantly inversely correlated with those in the mean BP. Thus, salt-induced modulation of endogenous NO may be related to salt sensitivity. To clarify whether the NO response to salt intake modulation contributes to the pathogenesis of hypertension or to that of salt sensitivity, we further examined the effect of salt intake modulation on the plasma NOx concentration in normotensive subjects. No responses of the plasma NOx concentration and BP after the change from the normal- to the low-salt diets were found in either the normotensive subjects or the group 2 EH patients, whereas there was a significant increase in the plasma NOx concentration level and a decrease in BP in the salt-sensitive group, indicating that the NO response to salt intake might contribute to the pathogenesis of salt sensitivity in human hypertension.

These lines of evidence raised another possibility, that the changes in plasma NOx concentration are in response to the changes in BP. Because in group 2 the plasma NOx concentration was significantly decreased and it increased without any changes in BP after the series of salt loading and restriction, the changes in plasma NOx concentration may not be simply in response to the changes in BP. It has been well documented that the L-arginine–NO pathway is impaired in salt-sensitive experimental hypertension by reduced bioavailability of endothelial NO.21 22 23 24 25 In salt-sensitive Dahl rats, the perfusate for isolated kidney has been reported to contain less NOx than that in salt-resistant rats.26 However, to the best of our knowledge, this is the first report for the significant role of NO in salt sensitivity in human hypertension.

Whereas high salt intake resulted in a decrease in plasma NOx concentration, the plasma NE concentration also was reduced by salt loading. However, the mechanism for the change in plasma NOx concentration is independent of the changes in plasma NE, because no significant correlation was found between plasma NE and salt sensitivity.

Mechanism for NO Synthesis Suppression by Salt Loading
The suppressant effect of high salt intake on plasma NOx concentration could occur by several mechanisms, including altered transport of L-arginine through the endothelial membrane, decreased activity of the enzyme NOS, and an increased breakdown or excretion of NO.27 The present study was focused on the endogenous NOS antagonist ADMA, which also inhibits L-arginine uptake into endothelial cells, and showed that its plasma level was significantly increased after high salt intake and decreased after salt restriction. The normal plasma level of ADMA was shown to be {approx}1 to 2 µmol/L.11 This level of ADMA alone is probably not sufficient to inhibit NOS activity. However, because methylarginines are concentrated within the cell,28 a moderate increase in plasma ADMA concentration, as observed in the present study, may reflect a higher increase of the compound in the vicinity of the NOS and thus result in a decrease in plasma NOx concentration. The significant inverse correlation of the percent change in plasma ADMA with the percent change in plasma NOx concentration after both salt loading and restriction may be consistent with this assumption. Although the origin of elevated plasma ADMA is unknown, the concentration of ADMA was shown to be increased substantially in the plasma of patients with uremia,11 hypertension,29 heart failure,30 and severe atherosclerosis31 ; in hypercholesterolemic rabbits32 ; in rats with heart failure28 ; and in the urine of salt-loaded Dahl salt-sensitive rats.15 An increased production by methylation of L-arginine33 and degradation of methylated tissue protein34 and/or decreased metabolism to citrulline by dimethylarginine dimethylaminohydrolase33 and excretion from the kidney is likely to contribute to the elevation of plasma ADMA, but this issue still remains to be elucidated.

Limitations of the Study
The effects of both salt loading and restriction were examined only in the patients with EH. Therefore, it is not clear whether salt intake generally affects NO synthesis in humans. Because the BP of the present EH patients was elevated mildly to moderately, the finding may be applied to the normotensive subjects.

Received June 22, 1999; revision received September 17, 1999; accepted September 23, 1999.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 

  1. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524–526.[Medline] [Order article via Infotrieve]
  2. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:1774–1777.
  3. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res. 1989;65:1–21.[Free Full Text]
  4. Radomski M, Vallance P, Whitley GH, Foxwell N, Moncada S. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine-induced nitric oxide. Cardiovasc Res. 1993;27:1380–1382.[Abstract/Free Full Text]
  5. Deng X, Welch WJ, Wilcox CS. Renal vasoconstriction during inhibition of NO synthase: effects of dietary salt. Kidney Int. 1994;46:639–646.[Medline] [Order article via Infotrieve]
  6. Shultz PJ, Tolins JP. Adaptation to increased dietary salt intake in the rat: role of endogenous nitric oxide. J Clin Invest. 1993;91:1993–1997.
  7. Takenaka T, Forster H, De Micheli A, Epstein M. Impaired myogenic responsiveness of renal microvessels in Dahl salt-sensitive rats. Circ Res. 1992;71:471–480.[Abstract/Free Full Text]
  8. Coyle P. High NaCl predisposes Dahl rats to cerebral infarction after middle cerebral artery occlusion. Hypertension. 1988;12:96–101.[Abstract/Free Full Text]
  9. Campese VM, Tawadrous M, Bigazzi R, Bianchi S, Mann AS, Oparil S, Raiji L. Salt intake and plasma atrial natriuretic peptide and nitric oxide in hypertension. Hypertension. 1996;28:335–340.[Abstract/Free Full Text]
  10. Fickling SA, Leone A, Nussey S, Vallance P, Whitley G. Synthesis of NG, NG-dimethylarginine by human endothelial cells. Endothelium. 1993;1:137–140.
  11. Macallister RJ, Fickling SA, Whitley GSJ, Vallance P. Metabolism of methylarginines by human vasculature: implications for the regulation of nitric oxide synthesis. Br J Pharmacol. 1994;112:43–48.[Medline] [Order article via Infotrieve]
  12. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572–575.[Medline] [Order article via Infotrieve]
  13. Kakimoto Y, Akazawa S. Isolation and identification of NG, NG- and NG, NG-dimethylarginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J Biol Chem. 1970;245:5751–5758.[Abstract/Free Full Text]
  14. Macallister RJ, Whitley GSJ, Vallance P. Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int. 1994;45:737–742.[Medline] [Order article via Infotrieve]
  15. Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai T, Wada Y, Yasukawa H, Iwai G, Okuda S, Imaizumi T. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension. 1997;29:242–247.[Abstract/Free Full Text]
  16. Higashi Y, Oshima T, Watanabe M, Matsuura H, Kajiyama G. Renal response to L-arginine in salt-sensitive patients with essential hypertension. Hypertension. 1996;27:643–648.[Abstract/Free Full Text]
  17. Stein MC, Richard N, Michael B, Margaret W, Alastair JJW. Dietary sodium intake modulates vasodilation mediated by nitroprusside but not by methacholine in the human forearm. Hypertension. 1995;25:1220–1223.[Abstract/Free Full Text]
  18. Tschudi MR, Mesaros S, Luscher TF, Malinski T. Direct in situ measurement of nitric oxide in mesenteric resistance arteries: increased decomposition by superoxide in hypertension. Hypertension. 1996;27:32–35.[Abstract/Free Full Text]
  19. Swei A, Lacy F, DeLano FA, Schmid Schonbein GW. Oxidative stress in the Dahl hypertensive rat. Hypertension. 1997;30:1628–1633.[Abstract/Free Full Text]
  20. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation. 1998;97:2222–2229.[Abstract/Free Full Text]
  21. Luscher TF, Raji L, Vanhoutte PM. Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension. 1987;9:157–163.[Abstract/Free Full Text]
  22. Chen PY, Sanders PW. L-Arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest. 1991;88:1559–1567.
  23. Chen PY, Sanders PW. Role of nitric oxide synthesis in salt-sensitive hypertension in Dahl/Rapp rats. Hypertension. 1993;22:812–818.[Abstract/Free Full Text]
  24. Miyata N, Zou AP, Mattson DL, Cowley AW Jr. Renal medullary interstitial infusion of L-arginine prevents hypertension in Dahl salt-sensitive rats. Am J Physiol. 1998;275:R1667–R1673.
  25. Chen PY, Gladish RD, Sanders PW. Vascular smooth muscle nitric oxide synthase anomalies in Dahl/Rapp salt-sensitive rats. Hypertension. 1998;31:918–924.[Abstract/Free Full Text]
  26. Hayakawa H, Hirata Y, Suzuki E, Sugimoto T, Hatsuoka H, Kikuchi K, Nagano T, Hirobe M, Sugimoto T. Mechanisms for altered endothelium-dependent vasorelaxation in isolated kidney from experimental hypertensive rats. Am J Physiol. 1993;264:H1535–H1541.[Abstract/Free Full Text]
  27. Singh N, Dhalla AK, Seneviratne C, Singal PK. Oxidative stress and heart failure. Mol Cell Biochem. 1995;147:77–81.[Medline] [Order article via Infotrieve]
  28. Feng Q, Lu X, Fortin AJ, Pettersson A, Hedner T, Kline RL, Arnold JMO. Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure. Cardiovasc Res. 1998;37:667–675.[Abstract/Free Full Text]
  29. Goonasekera CDA, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens. 1997;15:901–909.[Medline] [Order article via Infotrieve]
  30. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci. 1998;62:2425–2430.[Medline] [Order article via Infotrieve]
  31. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation. 1997;95:2068–2074.[Abstract/Free Full Text]
  32. Boger RH, Bode-Boger SM, Brandes RP, Phivthong-ngam L, Bohme M, Nafe R, Mugge A, Frolich JC. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation. 1997;96:1282–1290.[Abstract/Free Full Text]
  33. McAllister RJ, Fickling SA, Whitley GSJ, Vallance P. Metabolism of methylarginines by human vasculature: implications for the regulation of nitric oxide synthesis. Br J Pharmacol. 1994;112:43–48.
  34. McDermott JR. Studies on the catabolism of NG-methylarginine, NG, N'G-dimethylarginine and NG, NG-dimethylarginine in the rabbit. Biochem J. 1976;154:179–184.[Medline] [Order article via Infotrieve]



This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
H. Oberleithner, C. Riethmuller, H. Schillers, G. A. MacGregor, H. E. de Wardener, and M. Hausberg
Plasma sodium stiffens vascular endothelium and reduces nitric oxide release
PNAS, October 9, 2007; 104(41): 16281 - 16286.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
H. J. Adrogue and N. E. Madias
Sodium and Potassium in the Pathogenesis of Hypertension
N. Engl. J. Med., May 10, 2007; 356(19): 1966 - 1978.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. Konishi, K. Sydow, and J. P. Cooke
Dimethylarginine Dimethylaminohydrolase Promotes Endothelial Repair After Vascular Injury
J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1099 - 1105.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. A. Banday, A. B. Muhammad, F. R. Fazili, and M. Lokhandwala
Mechanisms of Oxidative Stress-Induced Increase in Salt Sensitivity and Development of Hypertension in Sprague-Dawley Rats
Hypertension, March 1, 2007; 49(3): 664 - 671.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
Y. Fang, J.-J. Mu, L.-C. He, S.-C. Wang, and Z.-Q. Liu
Salt Loading on Plasma Asymmetrical Dimethylarginine and the Protective Role of Potassium Supplement in Normotensive Salt-Sensitive Asians
Hypertension, October 1, 2006; 48(4): 724 - 729.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. Seidlerova, J. A. Staessen, M. Maillard, T. Nawrot, H. Zhang, M. Bochud, T. Kuznetsova, T. Richart, L. M. Van Bortel, H. A. Struijker-Boudier, et al.
Association Between Arterial Properties and Renal Sodium Handling in a General Population
Hypertension, October 1, 2006; 48(4): 609 - 615.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
J. C. G. Magalhaes, A. B. da Silveira, D. L. Mota, and A. D. O. Paixao
Renal function in juvenile rats subjected to prenatal malnutrition and chronic salt overload
Exp Physiol, May 1, 2006; 91(3): 611 - 619.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
F. Perticone, A. Sciacqua, R. Maio, M. Perticone, R. Maas, R. H. Boger, G. Tripepi, G. Sesti, and C. Zoccali
Asymmetric Dimethylarginine, L-Arginine, and Endothelial Dysfunction in Essential Hypertension
J. Am. Coll. Cardiol., August 2, 2005; 46(3): 518 - 523.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
P. Ravani, G. Tripepi, F. Malberti, S. Testa, F. Mallamaci, and C. Zoccali
Asymmetrical Dimethylarginine Predicts Progression to Dialysis and Death in Patients with Chronic Kidney Disease: A Competing Risks Modeling Approach
J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2449 - 2455.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Herrera and J. L. Garvin
Recent Advances in the Regulation of Nitric Oxide in the Kidney
Hypertension, June 1, 2005; 45(6): 1062 - 1067.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
J. P Cooke
ADMA: its role in vascular disease
Vascular Medicine, May 1, 2005; 10(2_suppl): S11 - S17.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
H. Sugita, M. Fujimoto, T. Yasukawa, N. Shimizu, M. Sugita, S. Yasuhara, J. A. J. Martyn, and M. Kaneki
Inducible Nitric-oxide Synthase and NO Donor Induce Insulin Receptor Substrate-1 Degradation in Skeletal Muscle Cells
J. Biol. Chem., April 8, 2005; 280(14): 14203 - 14211.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Cakir, O. Ozcan, H. Yaman, E. O. Akgul, C. Bilgi, M. K. Erbil, and Z. Yesilova
Elevated Plasma Concentration of Asymmetric Dimethylarginine That Is Reduced by Single Dose Testosterone Administration in Idiopathic Hypogonadotropic Hypogonadism Patients
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1651 - 1654.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. E. Gates, H. Tanaka, W. R. Hiatt, and D. R. Seals
Dietary Sodium Restriction Rapidly Improves Large Elastic Artery Compliance in Older Adults With Systolic Hypertension
Hypertension, July 1, 2004; 44(1): 35 - 41.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
K. Sydow, B. Hornig, N. Arakawa, S. M Bode-Boger, D. Tsikas, T. Munuzel, and R. H Boger
Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA
Vascular Medicine, May 1, 2004; 9(2): 93 - 101.
[Abstract] [PDF]


Home page
CirculationHome page
J. P. Cooke
Asymmetrical Dimethylarginine: The Uber Marker?
Circulation, April 20, 2004; 109(15): 1813 - 1818.
[Full Text] [PDF]


Home page
HypertensionHome page
T. Osanai, M. Saitoh, S. Sasaki, H. Tomita, T. Matsunaga, and K. Okumura
Effect of Shear Stress on Asymmetric Dimethylarginine Release From Vascular Endothelial Cells
Hypertension, November 1, 2003; 42(5): 985 - 990.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
A. D. Dobrian, S. D. Schriver, T. Lynch, and R. L. Prewitt
Effect of salt on hypertension and oxidative stress in a rat model of diet-induced obesity
Am J Physiol Renal Physiol, October 1, 2003; 285(4): F619 - F628.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. L. Houghton, D. S. Strogatz, M. T. Torosoff, V. E. Smith, S. A. Fein, P. A. Kuhner, E. F. Philbin, and A. A. Carr
African Americans With LVH Demonstrate Depressed Sensitivity of the Coronary Microcirculation to Stimulated Relaxation
Hypertension, September 1, 2003; 42(3): 269 - 276.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. C. Stuhlinger, R. K. Oka, E. E. Graf, I. Schmolzer, B. M. Upson, O. Kapoor, A. Szuba, M. R. Malinow, T. C. Wascher, O. Pachinger, et al.
Endothelial Dysfunction Induced by Hyperhomocyst(e)inemia: Role of Asymmetric Dimethylarginine
Circulation, August 26, 2003; 108(8): 933 - 938.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
N. Toda and T. Okamura
The Pharmacology of Nitric Oxide in the Peripheral Nervous System of Blood Vessels
Pharmacol. Rev., June 1, 2003; 55(2): 271 - 324.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Hermenegildo, P. Medina, M. Peiro, G. Segarra, J. M. Vila, J. Ortega, and S. Lluch
Plasma Concentration of Asymmetric Dimethylarginine, an Endogenous Inhibitor of Nitric Oxide Synthase, Is Elevated in Hyperthyroid Patients
J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5636 - 5640.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. F. Kahn, S. J. Duffy, D. Tomasian, M. Holbrook, L. Rescorl, J. Russell, N. Gokce, J. Loscalzo, and J. A. Vita
Effects of Black Race on Forearm Resistance Vessel Function
Hypertension, August 1, 2002; 40(2): 195 - 201.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
S. Shaldon
Dietary salt restriction and drug-free treatment of hypertension in ESRD patients: a largely abandoned therapy
Nephrol. Dial. Transplant., July 1, 2002; 17(7): 1163 - 1165.
[Full Text] [PDF]